近日，《JAMA Neurology》期刊正式刊登了Primec针对肌萎缩侧索硬化症（ALS）的Paradigm IIb期临床试验数据。该研究由NeuroSense Therapeutics Ltd主导，结果显示Primec在ALS治疗中不仅表现出具有临床意义的疗效指标，还展现出明确的生物学活性证据。
试验数据证实，Primec在延缓疾病进展、改善患者功能评分等方面产生积极影响，同时通过生物标志物分析验证了其作用于疾病相关通路的能力。这一突破为ALS治疗领域提供了新的方向，也为后续临床开发奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.